Z Gastroenterol 2018; 56(08): e312-e313
DOI: 10.1055/s-0038-1668950
Kurzvorträge
Gastroenterologische Onkologie
Multimodale Therapie des HCC: Ergebnisse und Prognose – Donnerstag, 13. September 2018, 14:00 – 15:36, 22b
Georg Thieme Verlag KG Stuttgart · New York

Applicability of clinical scoring systems after transarterial chemoembolisation in the bridging to transplant setting

I Mohr
1   Universitätsklinikum Heidelberg, Klinik für Gastroenterologie, Infektionskrankheiten und Vergiftungen, Heidelberg, Deutschland
,
M Vogeler
1   Universitätsklinikum Heidelberg, Klinik für Gastroenterologie, Infektionskrankheiten und Vergiftungen, Heidelberg, Deutschland
,
J Pfeiffenberger
1   Universitätsklinikum Heidelberg, Klinik für Gastroenterologie, Infektionskrankheiten und Vergiftungen, Heidelberg, Deutschland
,
D Sprengel
2   Universitätsklinikum Heidelberg, Diagnostische und Interventionelle Radiologie, Heidelberg, Deutschland
,
M Klauss
2   Universitätsklinikum Heidelberg, Diagnostische und Interventionelle Radiologie, Heidelberg, Deutschland
,
B Radeleff
2   Universitätsklinikum Heidelberg, Diagnostische und Interventionelle Radiologie, Heidelberg, Deutschland
3   Sana Klinikum Hof, Klinik für Radiolgie, Hof, Deutschland
,
C Springfeld
4   Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen/Onkologie, Heidelberg, Deutschland
,
T Longerich
5   Universitätsklinikum Heidelberg, Institut fur Allgemeine Pathologie, Heidelberg, Deutschland
,
R von Haken
6   Universitätsklinikum Heidelberg, Klinik für Anästhesiologie, Heidelberg, Deutschland
,
M Mieth
7   Universitätsklinikum Heidelberg, Chirurgische Klinik, Heidelberg, Deutschland
,
A Mehrabi
7   Universitätsklinikum Heidelberg, Chirurgische Klinik, Heidelberg, Deutschland
,
KH Weiss
1   Universitätsklinikum Heidelberg, Klinik für Gastroenterologie, Infektionskrankheiten und Vergiftungen, Heidelberg, Deutschland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. August 2018 (online)

Auch verfügbar auf
 

Background:

Several scoring systems have been proposed to predict the outcome of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) in palliative treatment indication. However, the application of these scores to the bridging to transplant setting is poorly validated.

Aim:

Our study evaluated whether other prognostic scores such as ART, CLIP, ALBI, APRI, SNACOR, HAP, Stat Score, Child pugh (CPS) or BCLC score differ for patients with TACE as bridging therapy to liver transplant (LTx) versus patients treated with TACE in palliative intention.

Method:

493 TACE procedures were performed from January 2011 to January 2018 in patients presenting with HCC. 92 patients had been treated with TACE as bridging therapy to LTx, 128 were treated in palliative intention. Primary endpoint was overall survival tested between the scores listed above. Data was analyzed out of a prospectively collected SPSS database.

Results:

Concerning median overall survival (OS) SNACOR (p = 0,001), CPS (p = 0,047) and BCLC (p = 0,001) showed significant difference in the bridging to LTx group in the univariate analysis. Among multivariate analysis, only SNACOR showed significant difference in this group (p = 0.009). All scores reached statistical significance (p = 0,001) among univariate analysis in the palliative cohort. Among multivariate analysis, APRI score (p = 0,003), State Score (p = 0,001), CPS (p = 0,001) and BCLC (p = 0,006) revealed statistical significance.

Conclusion:

Our results are inconsistent with previous studies that patients after TACE should be assessed by ART score in general. Scoring-Systems to predict OS after TACE should be stratified among patient subgroups and used with caution. In our cohort of patients receiving TACE as bridging therapy to LTx, SNACOR reflected best OS.